Inogen To Recognize National COPD Awareness Month At The Nasdaq Stock Market Closing Bell Ceremony
GOLETA, Calif., Nov. 18, 2015 (GLOBE NEWSWIRE) -- Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced it will ring The Nasdaq Stock Market closing bell in New York City on November 19, 2015 in honor of National COPD Awareness Month.
Inogen was founded in 2001 to improve the life of a beloved grandmother with Chronic Obstructive Pulmonary Disease (COPD). Based on 2014 industry data, the Company believes it was the leading worldwide manufacturer of portable oxygen concentrators, as well as the largest provider of portable oxygen concentrators to Medicare patients, as measured by dollar volume. According to the American Lung Association, COPD is the 3rd leading cause of death in the US and it is estimated that more than half of COPD patients remain unaware and undiagnosed. November is National COPD Awareness Month and Inogen's goal is to raise awareness of COPD so that others may seek treatment to live longer and more fulfilling lives.
Inogen's Chief Financial Officer, Alison Bauerlein said, "It was one of Inogen's proudest moments to give my grandmother, Mae, our first portable oxygen concentrator, which she inspired. Mae was diagnosed with COPD early and was able to live active and fulfilling years with proper treatment. It is our hope that others with breathing difficulties seek screening for COPD and can receive the appropriate treatment."
A live webcast of the Closing Bell ceremony will be available at https://new.livestream.com/nasdaq/live.
Inogen has used, and intends to continue to use, its Investor Relations website, http://investor.inogen.com/, as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. For more information, visit http://investor.inogen.com/.
Use of Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements concerning or implying future financial performance or that Inogen can maintain market share. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to, risks arising from the possibility that Inogen will not realize anticipated revenue; the impact of reduced reimbursement rates, including in connection with the implementation of the competitive bidding and the Center for Medicare and Medicaid Services (CMS) rules; the possible loss of key employees, customers, or suppliers; and intellectual property risks if Inogen is unable to secure and maintain patent or other intellectual property protection for the intellectual property used in its products. In addition, Inogen's business is subject to numerous additional risks and uncertainties, including, among others, risks relating to market acceptance of its products; its ability to successfully launch new products and applications; competition; its sales, marketing and distribution capabilities; its planned sales, marketing, and research and development activities; interruptions or delays in the supply of components or materials for, or manufacturing of, its products; seasonal variations in customer operations; unanticipated increases in costs or expenses; and risks associated with international operations. Information on these and additional risks, uncertainties, and other information affecting Inogen's business and operating results are contained in Inogen's Annual Report on Form 10-K for the year ended December 31, 2014 and in Inogen's subsequent reports filed with the Securities and Exchange Commission, including Inogen's Quarterly Report on Form 10-Q for the period ended September 30, 2015. These forward-looking statements speak only as of the date hereof. Inogen disclaims any obligation to update these forward-looking statements except as may be required by law.
About Inogen
Inogen is innovation in oxygen therapy. We are a medical technology company that develops, manufactures and markets innovative oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
For more information, please visit www.inogen.com.
CONTACT: Investor Relations Contact: ir@inogen.net 805-562-0500 ext 7 Media Contact: Byron Myers 805-562-0503
